Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational study.

Fadini, Gian Paolo et al.·The Lancet regional health. Europe·2025·
RPEP-108792025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational study.
Published In:
The Lancet regional health. Europe, 59, 101499 (2025)
Database ID:
RPEP-10879

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-10879·https://rethinkpeptides.com/research/RPEP-10879

APA

Fadini, Gian Paolo; Giaccari, Andrea; Broglio, Fabio; Nollino, Laura; Fattor, Bruno; Anichini, Roberto; Meregalli, Giancarla; Avogaro, Angelo; Consoli, Agostino. (2025). Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational study.. The Lancet regional health. Europe, 59, 101499. https://doi.org/10.1016/j.lanepe.2025.101499

MLA

Fadini, Gian Paolo, et al. "Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational study.." The Lancet regional health. Europe, 2025. https://doi.org/10.1016/j.lanepe.2025.101499

RethinkPeptides

RethinkPeptides Research Database. "Type 2 diabetes remission after initiation of GLP-1 receptor..." RPEP-10879. Retrieved from https://rethinkpeptides.com/research/fadini-2025-type-2-diabetes-remission

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.